Nahdi Medical Company

TADAWUL:4164.SR

119.2 (SAR) • At close January 15, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) SAR.

2024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q1
Revenue 2,353.2522,472.72,257.4972,214.252,162.92,231.4852,105.0362,138.2422,158.9832,239.4692,079.4941,973.232,041.7392,070.1361,981.1111,986.1412,135.552,423.5722,260.258
Cost of Revenue 1,502.31,5341,402.8471,349.191,288.7281,335.3961,218.1131,306.4351,247.9261,313.1661,227.7671,166.0231,183.9431,210.1681,201.41,276.1751,357.3221,476.5961,407.173
Gross Profit 850.952938.7854.65865.06874.173896.09886.923831.807911.056926.303851.727807.206857.796859.968779.711709.967778.228946.977853.085
Gross Profit Ratio 0.3620.380.3790.3910.4040.4020.4210.3890.4220.4140.410.4090.420.4150.3940.3570.3640.3910.377
Reseach & Development Expenses 0000000000000000000
General & Administrative Expenses 88.85285.87780.584-186.20792.16581.2780.369-173.67194.13681.08667.273-160.10863.5488.39160.41249.1881.87105.14689.795
Selling & Marketing Expenses 590.916585.22557.049-1,261.508559.569547.937548.631-1,286.21553.331552.186533.294-1,201.04525.301516.439494.948477.138583.907540.502448.797
SG&A 679.767671.097631.449-1,447.715651.734629.207629-1,459.881647.467633.273600.568-1,361.148588.841604.83555.36508.318665.777645.647538.592
Other Expenses -4.614-665.38.4383.7720.2160.0010.013-0.3863.1920.6061.0476.72.991000000
Operating Expenses 675.153665.3623.011702.79644.393613.167623.677694.553632.556620.491587.354692.776583.521600.331553.547518.747662.964639.236533.077
Operating Income 175.826273.4231.64865.06229.779282.922263.246153.892278.5305.812264.373159.829274.275259.637226.164210.89115.265307.741320.008
Operating Income Ratio 0.0750.1110.1030.3910.1060.1270.1250.0720.1290.1370.1270.0810.1340.1250.1140.1060.0540.1270.142
Total Other Income Expenses Net -16.521-12.81310.699-2.405-7.179-6.221-0.904-15.332-13.631-18.697-16.991-9.089-15.061-19.249-19.238-25.031-10.918-12.84-14.151
Income Before Tax 159.305260.607242.339182.602222.6276.702262.342138.56264.869287.114247.382150.74259.214240.388206.926178.386104.347294.901305.856
Income Before Tax Ratio 0.0680.1050.1070.0820.1030.1240.1250.0650.1230.1280.1190.0760.1270.1160.1040.090.0490.1220.135
Income Tax Expense -22.88312.8719.38912.0849.79511.751810.57511.05718.6079.8757.50811.76313.5611.90811.5811.2524.25811.25
Net Income 182.188247.736232.95170.518212.805264.952244.343127.985253.812268.507237.507143.232247.451226.828195.018166.80693.097270.643294.606
Net Income Ratio 0.0770.10.1030.0770.0980.1190.1160.060.1180.120.1140.0730.1210.110.0980.0840.0440.1120.13
EPS 1.41.911.791.311.642.041.880.981.952.071.831.11.91.741.50.760.932.712.95
EPS Diluted 1.41.911.791.311.642.041.880.981.952.071.831.11.91.741.50.760.932.712.95
EBITDA 364.161462.96428.926367.613395.602445.194436.94311.241440.952357.871410.067317.317337.398293.721363.496237.657155.649346.039358.306
EBITDA Ratio 0.1550.1870.1740.1420.1830.20.2070.140.2030.2020.1970.140.2030.1960.1830.120.0730.1430.159